Investigations of Silymarine Effects on Prognosis of Patients With Severe and Moderate Traumatic Brain Injury

Saeed Jafari, MD; Alireza Kamali, MD; Jila Mohseni, PhD; Ali Nazemi Rafi, MD; Hassan Solhi, MD

Objective • The purpose of this study was to evaluate Silymarine effects on prognosis of patients with severe and moderate traumatic brain injury. Study Design • This double blind, placebo-controlled clinical trial. Setting • Valiasr hospital hospital in Arak,Iran Subjects and Methods • Research was performed among patients between 15 and 65 years of age with severe moderate (Glasgow Coma Scale score 9 to 12) and moderate (GCS 3 to 8) traumatic brain injury (TBI). Patients were divided into two groups (Each group: 40 patients). Patients assigned to the control groupwere receiving all standard treatments. Patients in case groups were administered 140 mg of silymarin every 8 hours for 7 days. We Checked the Glasgow Outcome Scale (GOS), GCS, age, gender, location, mechanism of trauma, site of accident and the incidence time of accident to arrival at emergency unite. Statistical analysis was conducted using SPSS (SPSS version 18; Chicago, IL). Results • Our findings suggested that there was no a significant difference between intervention group and control in terms of parameters as GOS, GCS, age, gender, location, mechanism of trauma, and site of accident and the incidence time of accident to arrival at emergency unite (P > .05). Brain CT in two groups showed a significant difference (P = .002), where in the silymarin group there were more normal cases when comparing with control group. Conclusions • Silymarin did not reveal a significant effect for improving prognosis of patients with moderate and severe TBI.

I am a subscriber to ATHM and would like to read this article
I would like to purchase this article - $35.00
I would like to subscribe to ATHM for $55.00 and obtain access to this article